MISSION CRITICAL
The Dexcom G6 Continuous Glucose Monitoring (CGM) System is mission critical for empowering veterans to take control of their diabetes.
And it may be available at participating Veterans Affairs (VA) pharmacies.
*For a list of compatible devices, visit www.dexcom.com/compatibility
Empower veterans to take control of their diabetes
Dexcom G6 is a small, wearable sensor that sends glucose data directly to your patient's smart device,* making it easier for them to manage their diabetes — without fingersticks.† It also sends patients alerts when they go high or low, empowering them to make better treatment decisions.
And may be covered for qualified veterans.‡
†If your patients’ glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, they will need to use a blood glucose meter to make diabetes treatment decisions.
See Full Dexcom G6 Specifications
‡For a complete description of Veterans Affairs coverage criteria and additional information, please see the Department of Veterans Affairs Criteria for Use Memorandum, January 31, 2019. A patient must be seen at a VA healthcare facility or a VA Community Care Network clinic to be eligible to receive coverage.
CGM coverage and reimbursement information is being provided on an “as is” basis at the time of publication, with no express or implied warranty of any kind, and should be used solely for informational purposes. All coding, coverage policies, and reimbursement information are subject to change without notice. Coverage for CGM depends on a variety of factors, and coverage conditions will apply. Not all patients will be covered for Dexcom G6 or any other CGM device. Dexcom, Inc. does not represent or guarantee coverage under any applicable payor, program, or plan. The information provided herein does not constitute professional or legal advice on coverage or reimbursement and should be used at your sole liability and discretion. Dexcom, Inc. does not represent or warrant that any of the information being provided is true or correct and you agree to hold Dexcom, Inc. harmless in the event of any loss, damage, liability, expense, or claim arising from your use or reliance on this coverage or reimbursement information for billing purposes. Before submitting any claims for reimbursement to any payor, it is the provider’s sole responsibility to verify compliance with the payor’s current coverage conditions.
How to Prescribe Dexcom G6
E-Prescribe to the VA Pharmacy
You can choose whether your qualified‡ patients will fill their order at a participating VA Pharmacy or through the VA Mail Order Pharmacy.
Prescription Filled by VA Pharmacy
The VA Pharmacy staff will fill the prescription, following up with you or your patient if needed.
VA Pharmacy Follow-Up
The VA Pharmacy staff will follow up with you or your patient for refills.
Product Components |
Product NDC Code |
Quantity |
Refills |
|||
---|---|---|---|---|---|---|
![]() |
DEXCOM G6
|
08627-0091-11 |
1 | Once a year | ||
![]() |
DEXCOM G6
|
08627-0016-01 |
1 | Every 3 months | ||
![]() |
DEXCOM G6
|
08627-0053-03 |
3 sensors per box | Every 30 days |
‡For a complete description of Veterans Affairs coverage criteria and additional information, please see the Department of Veterans Affairs Criteria for Use Memorandum, January 31, 2019. A patient must be seen at a VA healthcare facility or a VA Community Care Network clinic to be eligible to receive coverage.
CGM coverage and reimbursement information is being provided on an “as is” basis at the time of publication, with no express or implied warranty of any kind, and should be used solely for informational purposes. All coding, coverage policies, and reimbursement information are subject to change without notice. Coverage for CGM depends on a variety of factors, and coverage conditions will apply. Not all patients will be covered for Dexcom G6 or any other CGM device. Dexcom, Inc. does not represent or guarantee coverage under any applicable payor, program, or plan. The information provided herein does not constitute professional or legal advice on coverage or reimbursement and should be used at your sole liability and discretion. Dexcom, Inc. does not represent or warrant that any of the information being provided is true or correct and you agree to hold Dexcom, Inc. harmless in the event of any loss, damage, liability, expense, or claim arising from your use or reliance on this coverage or reimbursement information for billing purposes. Before submitting any claims for reimbursement to any payor, it is the provider’s sole responsibility to verify compliance with the payor’s current coverage conditions.
Eligibility Requirements for
Veterans with T1D or T2D
To be eligible for Dexcom G6 coverage under Veterans Affairs, a healthcare provider must verify that the patient meets the following qualifying criteria:
- Has diabetes
- Performs frequent blood glucose monitoring (BGM) testing (≥4x/day)
- Takes ≥3 daily injections of insulin or uses an insulin pump
- Has the skillset and knowledge to use CGM successfully
- Has agreed to follow up in the clinic a minimum of every 6 months
- And, is one or more of the following:
- At risk for hypoglycemia
- Unable to meet glycemic control, despite adherence to the treatment regimen
- Performs job-related activities where a hypoglycemic event could put them at risk of harm
- Unable to perform self-monitoring of blood glucose due to disability or disease
For a complete description of Veterans Affairs coverage criteria and additional information, please see the Department of Veterans Affairs Criteria for Use Memorandum, January 31, 2019. A patient must be seen at a VA healthcare facility or a VA Community Care Network clinic to be eligible to receive coverage.
CGM coverage and reimbursement information is being provided on an “as is” basis at the time of publication, with no express or implied warranty of any kind, and should be used solely for informational purposes. All coding, coverage policies, and reimbursement information are subject to change without notice. Coverage for CGM depends on a variety of factors, and coverage conditions will apply. Not all patients will be covered for Dexcom G6 or any other CGM device. Dexcom, Inc. does not represent or guarantee coverage under any applicable payor, program, or plan. The information provided herein does not constitute professional or legal advice on coverage or reimbursement and should be used at your sole liability and discretion. Dexcom, Inc. does not represent or warrant that any of the information being provided is true or correct and you agree to hold Dexcom, Inc. harmless in the event of any loss, damage, liability, expense, or claim arising from your use or reliance on this coverage or reimbursement information for billing purposes. Before submitting any claims for reimbursement to any payor, it is the provider’s sole responsibility to verify compliance with the payor’s current coverage conditions.
Request a meeting with a Federal Business Manager
A Dexcom Federal Business Manager will reach out to set up a virtual or in-person meeting to answer your questions about Dexcom G6.

Veterans Affairs FAQs

Contact Support

Telehealth Resources
*For a list of compatible devices, visit www.dexcom.com/compatibility
†If your patients’ glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, they will need to use a blood glucose meter to make diabetes treatment decisions.
‡For a complete description of Veterans Affairs coverage criteria and additional information, please see the Department of Veterans Affairs Criteria for Use Memorandum, January 31, 2019. A patient must be seen at a VA healthcare facility or a VA Community Care Network clinic to be eligible to receive coverage.
1 Beck RW, et al. JAMA. 2017; 317(4); 371-378.
2 Welsh JB, et al. Diabetes Technol Ther. 2019; 21(3).
3 Ruedy KJ, et al. J Diabetes Sci Technol 2017;11:1138-46.
4 Dexcom, data on file, 2020.
5 Pratley R, et al. JAMA. 2020;323(23):2397-2406.
6 Noar A, et al. A1C Reductions and Improved Patient-Reported Outcomes Following CGM Initiation in Insulin-Managed T2D. Presented at ADA 80th Scientific Sessions; June 12, 2020; Virtual.